A5041985732- Pharmaceutical Practices and Patient Outcomes
- Advanced Breast Cancer Therapies
- Microtubule and mitosis dynamics
- Chronic Lymphocytic Leukemia Research
- Cancer-related Molecular Pathways
- Cancer Treatment and Pharmacology
- Gastric Cancer Management and Outcomes
- Innovations in Medical Education
- Esophageal Cancer Research and Treatment
- Lymphoma Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Colorectal and Anal Carcinomas
- Health Sciences Research and Education
- Colorectal Cancer Surgical Treatments
- CAR-T cell therapy research
- Nausea and vomiting management
- Epilepsy research and treatment
- Pharmaceutical studies and practices
- Anesthesia and Pain Management
- Esophageal and GI Pathology
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
- Nutrition and Health in Aging
- Pharmacological Effects and Toxicity Studies
- Lung Cancer Diagnosis and Treatment
University of Colorado Denver
2018-2021
University of Colorado Cancer Center
2018-2021
University of Montana
2016-2020
University of Colorado Anschutz Medical Campus
2015-2020
University of Colorado Hospital
2019
University of Colorado Health
2019
University of Colorado Boulder
2019
University of Denver
2018
Central Baptist Hospital
2016
Medical University of South Carolina
2009-2014
Polyoma virus BK–induced hemorrhagic cystitis is an important cause of morbidity after hematopoietic stem cell transplantation (HSCT). Fluoroquinolones have been shown in vitro to inhibit BK viral replication by direct inhibition the BK-encoded DNA gyrase. We hypothesized that extended prophylaxis with ciprofloxacin may decrease incidence severe (grades 3 and 4) virus–associated (sBKHC) HSCT. retrospectively collected patient transplant data, as well sBKHC, for all consecutive patients...
Despite the recent onslaught of approved medications in oncology, acute myeloid leukemia (AML) has been a disease state bereft pharmaceutical development for decades. The long-standing first-line regimen, 7 + 3, was developed 1973. A group four physicians at Roswell Park Memorial Institute built upon prior combinations daunorubicin and cytarabine to find optimal combination days 3 (Lichtman, 2013). This regimen undergone multiple modifications patient performance status-based...
The rising cost of pharmaceuticals and, in particular, cancer drugs has made headline news recent years. Several factors contribute to increasing costs and the burden this places on health care system patients. Some these include costly pharmaceutical research development, longer clinical trials required achieve drug approval, manufacturing for complex compounds, economic principles surrounding oncology pricing. Strategies control have been proposed, some already implemented mitigate such as...
Abstract Purpose: The purpose of this study was to evaluate the rational combination TORC1/2 inhibitor TAK-228 and Aurora A kinase alisertib in preclinical models triple-negative breast cancer (TNBC) conduct a phase I dose escalation trial patients with advanced solid tumors. Experimental Design: TNBC cell lines patient-derived xenograft (PDX) were treated alisertib, TAK-228, or evaluated for changes proliferation, cycle, mTOR pathway modulation, terminal cellular fate, including apoptosis...
Objective: This article summarizes the background, clinical trials, and place in therapy for first two anti-CD19 monoclonal antibodies that have been recently FDA approved patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Summary: Treatment options are limited relapsed after or ineligible autologous stem cell transplant (ASCT) chimeric antigen receptor (CAR) T-cell therapy. Recent novel approvals started to change management strategies outcomes these patients....
At our institution, an increased incidence of hypersensitivity reactions was reported following standardization fosaprepitant as the preferred agent for prophylaxis chemotherapy induced nausea and vomiting (CINV) caused by highly emetogenic therapies. The purpose this evaluation to assess systemic (HSRs) infusions compared available literature.This is a retrospective review electronic health records adult patients who received their first dose CINV beginning January 1, 2017 through June 30,...
Introduction Chemotherapy-induced nausea and vomiting (CINV) can be a serious debilitating adverse effect that is highly feared by cancer patients. For patients receiving moderately emetogenic chemotherapy regimens at our institution in the ambulatory infusion center, palonosetron was selected as preferred serotonin (5-HT3) antagonist for CINV prophylaxis per 2016 NCCN Guidelines, when neurokinin1 not included prophylactic regimen. The purpose of this study to evaluate efficacy dexamethasone...